Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

BEST CARE for Recurrent NMIBC: BladdEr-Sparing Therapy and Cystectomy As TREatments

Award Number: R01CA289268
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2030

Group Awards By:

View Award Description

BEST CARE for Recurrent NMIBC: BladdEr-Sparing Therapy and Cystectomy As TREatments - PROJECT SUMMARY/ABSTRACT Bladder cancer is the 6th most common cancer in the US and the 4th most common cancer in males. Each year, more than 80,000 people in the US are diagnosed with bladder cancer and over 17,000 will die. The vast majority (74%) present with non-muscle invasive bladder cancer (NMIBC). NMIBC has the oldest median age at diagnosis, intensive surveillance requirements, high recurrence and progression rates (up to 80%), and one of the greatest lifetime treatment costs of all cancers. Treatment options following recurrence of high-grade NMIBC include either BST (bladder sparing therapies with significant risk of cancer recurrence and/or progression) or radical cystectomy (a life-altering bladder removal surgery with substantial short-term morbidity and mortality). However, patients, their caregivers, and clinicians must make this complex treatment decision based on limited evidence since bladder cancer research remains underfunded relative to other common cancers, bladder cancer epidemiology cohorts are uncommon, RCTs have proven challenging to conduct, and risk stratification models are inadequate. Thus, there is a critical need for high-quality research in recurrent high-grade NMIBC across the full spectrum of outcomes to inform treatment decision-making. A recently established and unique cohort can be leveraged to address these evidence gaps. Specifically, the PCORI- funded Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) Study is a large pragmatic multisite study of patients with recurrent high-grade NMIBC patients who have selected BST or radical cystectomy to manage their cancer. The CISTO cohort is a unique resource in bladder cancer care and has potential to serve as the foundation for addressing critical questions relevant to optimal patient-centered management. However, longer-term follow up of the CISTO cohort is required to fully assess the comparative effectiveness and harms of management options for recurrent high-grade NMIBC. In addition, incorporating molecular factors associated with bladder cancer progression has the potential to improve clinical staging and augment risk prediction models. Finally, the financial impact of new BST options is an important consideration for patients with what is already one of the most expensive types of cancer to treat. Therefore, we propose the BEST CARE for Recurrent NMIBC study 1) To compare long-term outcomes (clinical and patient- reported) between patients undergoing BST or radical cystectomy, 2) To determine whether prediction of progression to muscle-invasive or metastatic bladder cancer is improved by molecular staging, and 3) To evaluate the impact of newly approved BST options on financial toxicity. We aim to fill substantial knowledge gaps about long-term oncologic and quality of life (QOL) outcomes, specifically addressing the continued role of radical cystectomy. If radical cystectomy is associated with better long-term clinical outcomes, less financial hardship, and similar long-term QOL as BST, in the context of additional information offered through molecular staging, this would be impactful to clinical NMIBC practice.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Cancer Cause and Prevention Research	000	2	9/5/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $925,430 )
2025	2025	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Cancer Cause and Prevention Research	000	2	7/10/2025	NON-COMPETING CONTINUATION	$925,430
														Subtotal = $925,430

Issue Date FY: 2024 ( Subtotal = $1,039,794 )
2024	2024	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Cancer Cause and Prevention Research	000	1	5/1/2024	NEW	$1,039,794
														Subtotal = $1,039,794

Grand Total All Awards = $1,965,224

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BEST CARE for Recurrent NMIBC: BladdEr-Sparing Therapy and Cystectomy As TREatments

Award Number: R01CA289268

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer